Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP
Rhinology
.
2022 Dec 1;60(6):474-478.
doi: 10.4193/Rhin22.053.
Authors
C Bachert
1
,
P W Hellings
2
,
V J Lund
3
,
W J Fokkens
4
,
C Hopkins
5
,
B Mayer
6
,
R H Chan
7
,
S G Smith
8
,
A R Sousa
7
,
R Alfonso-Cristancho
8
,
S Yang
9
,
On Behalf Of The Synapse Study Group On Behalf Of The Synapse Study Group
Affiliations
1
Ghent University and Ghent University Hospital, Belgium; University of Stockholm, Stockholm, Sweden.
2
Ghent University and Ghent University Hospital, Belgium; University of Leuven, Leuven, Belgium; Academic Medical Center, Amsterdam, the Netherlands.
3
University College London, London, UK; Royal National Throat Nose and Ear Hospital, UCLH, London, UK.
4
Academic Medical Center, Amsterdam, the Netherlands.
5
Guys and St Thomas' Hospital, King's College, London, UK.
6
Clinical Statistics, GSK, GSK House, Brentford, Middlesex, UK.
7
Respiratory Patient-Centred Outcomes, Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
8
Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
9
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
PMID:
36436220
DOI:
10.4193/Rhin22.053
Abstract
Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP.
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Quality of Life*
Substances
mepolizumab
Antibodies, Monoclonal, Humanized